Dr. Amy H. Case, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 198
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Alabama School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
GA license 66176 -
Critical Care Medicine (Internal Medicine) Physician
GA license 66176 -
Internal Medicine Physician
GA license 66176
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wellstar Kennestone Regional Medical Center Marietta, GA
- Piedmont Hospital, Inc Atlanta, GA
- Piedmont Fayette Hospital Fayetteville, GA
- Piedmont Newnan Hospital, Inc Newnan, GA
- Piedmont Mountainside Hospital Inc Jasper, GA
Medical groups
- Piedmont Providers LLC (530 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 198
- Services billed
- 970
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Test to measure expiratory airflow and volume | 164 | 93 |
| Test to determine lung volumes using sensors | 159 | 90 |
| Test to examine how well the lungs exchange gases | 158 | 91 |
| Test for exercise-induced lung stress | 149 | 81 |
| Established patient office or other outpatient visit, 20-29 minutes | 123 | 85 |
| Established patient office or other outpatient visit, 30-39 minutes | 88 | 57 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 52 | 44 |
| Established patient office or other outpatient visit, 40-54 minutes | 49 | 43 |
| X-ray of chest, 2 views | 27 | 13 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ofev (nintedanib esylate) | 117 |
| Prednisone Other prescribers in Austell, GA | 88 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Austell, GA | 63 |
| Pirfenidone | 33 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Austell, GA | 33 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Austell, GA | 31 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Austell, GA | 30 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Austell, GA | 21 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Austell, GA | 19 |
| Fluticasone Propionate Other prescribers in Austell, GA | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $4,336 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,250 |
|---|---|
| GlaxoSmithKline, LLC. | $69.74 |
| Amgen Inc. | $16.38 |
| Consulting Fee | $4,250 |
|---|---|
| Food and Beverage | $86.12 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 6, 2025 | Consulting Fee | $4,250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 4 companies. The companies reported $326,238 in research payments for these studies, mostly to the institutions running them.
- A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Pharmaceuticals, Inc. - Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Boehringer Ingelheim Pharmaceuticals, Inc. - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - Idiopathic Pulmonary Fibrosis Prospective Outcome Registry
Boehringer Ingelheim Pharmaceuticals, Inc. - A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SAR…
Boehringer Ingelheim Pharmaceuticals, Inc. - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim Pharmaceuticals, Inc. - Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
United Therapeutics Corporation · Completed · NCT05776225 - Phase 2 Double Blind Randomized Study in IPF and SSc ILD
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.